LB0003 Dazodalibep (VIB4920/HZN4920) in Sjögren's Subjects with an Unacceptable Symptom Burden: Safety and Efficacy from a Phase 2, Randomized, Double-Blind Study - St. Clair, E.W.; Alevizos, I.; Rees, W.; Wang, L.; Baer, A.; Ng, W.F.; Noaiseh, G.; Baldini, C. (Annals of the rheumatic diseases, 2023)
Keywords: Autoimmune diseases; CD40L protein; Clinical trials; COVID-19; Diarrhea; Double-blind studies; Eye diseases; Fatigue; Gammopathy; Long COVID; Morbidity; Neutropenia; Pain; Patients; Placebos; Quality of life; Randomized control trial; Rhinopharyngitis; Safety; Sjogren's syndrome; Sjögren syndrome; Statistical analysis; Stockholders; Randomized control trial; Sjögren syndrome; Safety